Nuvectis Pharma (NASDAQ:NVCT – Get Rating) had its price target lifted by analysts at HC Wainwright from $14.00 to $21.00 in a research note issued on Tuesday, The Fly reports. HC Wainwright’s target price would indicate a potential upside of 51.62% from the stock’s previous close.
Separately, Roth Capital reiterated a “buy” rating on shares of Nuvectis Pharma in a report on Sunday, April 17th.
Nuvectis Pharma stock traded down $1.21 during trading hours on Tuesday, reaching $13.85. 508 shares of the company’s stock were exchanged, compared to its average volume of 1,438,644. The stock’s 50 day moving average price is $9.03. Nuvectis Pharma has a twelve month low of $3.08 and a twelve month high of $19.97.
Nuvectis Pharma Company Profile (Get Rating)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.
- Get a free copy of the StockNews.com research report on Nuvectis Pharma (NVCT)
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Intuitive Surgical is an Intuitive Buy
- Follow The Money To Cigna
- The Low In Lordstown Motors May Not Be The Last
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.